- Home
- FHTX vs ORC Comparison
FHTX vs ORC Comparison
Compare FHTX & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- ORC
- Stock Information
- Founded
- FHTX 2015
- ORC 2010
- Country
- FHTX United States
- ORC United States
- Employees
- FHTX N/A
- ORC N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- ORC Real Estate Investment Trusts
- Sector
- FHTX Health Care
- ORC Real Estate
- Exchange
- FHTX Nasdaq
- ORC Nasdaq
- Market Cap
- FHTX 513.7M
- ORC 576.4M
- IPO Year
- FHTX 2020
- ORC 2013
- Fundamental
- Price
- FHTX $9.04
- ORC $7.73
- Analyst Decision
- FHTX Strong Buy
- ORC Buy
- Analyst Count
- FHTX 5
- ORC 2
- Target Price
- FHTX $16.00
- ORC $9.50
- AVG Volume (30 Days)
- FHTX 123.1K
- ORC 2.0M
- Earning Date
- FHTX 11-04-2024
- ORC 10-24-2024
- Dividend Yield
- FHTX N/A
- ORC 18.61%
- EPS Growth
- FHTX N/A
- ORC N/A
- EPS
- FHTX N/A
- ORC 1.01
- Revenue
- FHTX $25,515,000.00
- ORC $75,695,000.00
- Revenue This Year
- FHTX N/A
- ORC N/A
- Revenue Next Year
- FHTX $15.40
- ORC N/A
- P/E Ratio
- FHTX N/A
- ORC $7.51
- Revenue Growth
- FHTX N/A
- ORC N/A
- 52 Week Low
- FHTX $2.70
- ORC $6.73
- 52 Week High
- FHTX $10.25
- ORC $9.08
- Technical
- Relative Strength Index (RSI)
- FHTX 61.38
- ORC 45.37
- Support Level
- FHTX $7.95
- ORC $7.41
- Resistance Level
- FHTX $9.54
- ORC $7.79
- Average True Range (ATR)
- FHTX 0.56
- ORC 0.18
- MACD
- FHTX 0.19
- ORC -0.01
- Stochastic Oscillator
- FHTX 82.08
- ORC 41.03
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.